Biocomputing drug repurposing toward targeted therapies

Biocomputing drug repurposing toward targeted therapies

inhibition of the oncogenic activation of signalling pathways represents the main goal of drug discovery in oncology. Selective inhibitors of oncogenes such as mutated kinases and phosphatases have been identified mainly through traditional small molecule drug screenings aimed at identifying inhibitors of catalytic activity. However, ever-increasing failure rates, high costs, unsatisfactory saf...

Moving toward targeted therapies in acute myeloid leukemia.

Advances in genomic sequencing and insights into molecular leukemogenesis are opening the door to using targeted agents to tailor treatment for acute myeloid leukemia (AML) in individual patients. Although this shift away from traditional cytotoxic therapies represents an innovative approach to AML therapy, a number of obstacles stand in the way of widespread adoption of targeted therapy into d...

Drug Repurposing for Cancer Therapy.

In the mid-1980s, a French company geared its efforts toward developing a synthetic steroid capable of blocking the glucocorticoid receptor in order to potentially treat Cushing’s syndrome. Preclinical studies revealed that the compound developed, termed RU-38486, was indeed a potent antiglucocorticoid agent [1], yet with a caveat: if given to pregnant animals, it terminated pregnancy [2-4]. Th...

Advances in Targeted Drug Delivery

Advances in Targeted Drug Delivery